# Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects

> **NCT02146625** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CJ-40002

## Key facts

- **NCT ID:** NCT02146625
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02146625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02146625, "Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02146625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*